| PDF - Other (36kB) - Repository staff only | ||
| PDF - Other (205kB) - Repository staff only |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-549900
- DOI to cite this document:
- 10.5283/epub.54990
Abstract
Introduction There is a need for novel anxiolytics with improved side effect profiles compared to benzodiazepines. A promising candidate with alternative pharmacodynamics is the translocator protein ligand, etifoxine. Methods To get further insight into its mechanisms of action and side effects compared to the benzodiazepine alprazolam, we performed a double-blind, placebo-controlled, ...

Owner only: item control page

Download Statistics